What should I know about Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals is a US biopharmaceutical company, based in Conshohocken, Pennsylvania, focused on a liver disease called MASH (metabolic dysfunction-associated steatohepatitis), formerly known as NASH. According to its Q2 2026 earnings release, the company's first product, Rezdiffra, is a once-daily oral medicine that acts on the liver. Madrigal has built its business around that single therapeutic area. It trades on the Nasdaq under the ticker MDGL.
What are Madrigal Pharmaceuticals's main drugs?
Madrigal's only marketed product is Rezdiffra (resmetirom). It was the first drug approved by both the US FDA and the European Commission for MASH with moderate to advanced liver scarring, known as stage F2 to F3 fibrosis. According to the Q2 2026 earnings release, Rezdiffra net sales were $364.3 million in the quarter, up 71% from $212.8 million a year earlier. More than 49,000 patients were on treatment at 30 June 2026. Trailing 12-month sales were nearly $1.3 billion.
What is Madrigal Pharmaceuticals currently developing?
Madrigal is testing Rezdiffra in more advanced disease. Per its Q2 2026 earnings release, a Phase 3 outcomes trial is under way in patients with compensated MASH cirrhosis. The company also began dosing in a Phase 1 study in June 2026 of MGL-2086, an oral GLP-1 receptor agonist that is a derivative of orforglipron and is intended for use alongside Rezdiffra.
Is Madrigal Pharmaceuticals publicly traded, and how big is it?
Yes. Madrigal trades on the Nasdaq under the ticker MDGL. Its market capitalisation was about $11.3 billion on 7 October 2026. In the second quarter of 2026, its net sales of Rezdiffra, which is its only product, were $364.3 million, up 71% on the same quarter of 2025.